Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: Data from real-life follow-up of patients in the NOR-DMARD registry

Rheumatology (United Kingdom)

Volumn 51, Issue 9, 2012, Pages 1618-1627

  Kvamme, Maria K ^a   Lie, Elisabeth ^a   Kvien, Tore K ^a   Kristiansen, Ivar S ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Ankylosing spondylitis; Cost benefit analysis; Cost utility; Cost utility analysis; Economic evaluation; Health expenditures; Health care costs; Psoriatic arthritis; Quality adjusted life years; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB;

ABSENTEEISM; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTHROPATHY; ARTICLE; COST BENEFIT ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; NORWAY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY ADJUSTED LIFE YEAR; REGISTER; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; STUDENT T TEST;

ABSENTEEISM; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS; COST OF ILLNESS; FEMALE; HEALTH EXPENDITURES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NORWAY; OUTPATIENTS; PHYSICAL THERAPY MODALITIES; REGISTRIES; YOUNG ADULT;

EID: 84865344469     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes074     Document Type: Article

References (39)

1. Kvien TK, Heiberg MS, Lie E et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23(Suppl 39):s188-94.
2. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Kobelt G, Jönsson B. The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ 2008;8:95-106.
4. Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006;24:1221-32.
5. Schoels M, Wong J, Scott DL et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
6. Escorpizo R, Bombardier C, Boonen A et al. Worker productivity outcome measures in arthritis. J Rheumatol 2007;34:1372-80.
7. Beaton D, Bombardier C, Escorpizo R et al. Measuring worker productivity: frameworks and measures. J Rheumatol 2009;36:2100-9.
8. Neovius M, Simard JF, Askling J, ARTIS Study Group. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Ann Rheum Dis 2011;70:1010-5.
9. Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med 2006;56:18-27.
10. Geuskens GA, Burdorf A, Hazes JMW. Consequences of rheumatoid arthritis for performance of social roles-a literature review. J Rheumatol 2007;34:1248-60.
11. Olofsson T, Englund M, Saxne T et al. Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study. Ann Rheum Dis 2010;69:2131-6.
12. Neovius M, Simard JF, Klareskog L, Askling J, ARTIS Study Group. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis 2011;70:1407-14.
13. Augustsson J, Neovius M, Cullinane-Carli C et al. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis 2010;69:126-31.
14. Mittendorf T, Dietz B, Sterz R et al. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology 2008;47: 188-93.
15. Drummond MF, Sculpher MJ, Stoddart GL et al. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford: Oxford University Press, 2005.
16. Briggs A, Claxton K, Schulper M. Decision modelling for health economic evaluation. New York: Oxford University Press, 2006.
17. Tanaka E, Inoue E, Mannalithara A et al. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Mod Rheumatol 2010;20: 46-53.
18. Malhan S, Akbulut L, Bodur H, Tulunay C. Annual costs of rheumatoid arthritis in Turkey. Rheumatol Int 2010;30: 637-41.
19. Mora C, Gonzalez A, Diaz J, Quintana G. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia] [in Spanish]. Biomedica 2009;29: 43-50.
20. Kobelt G, Woronoff AS, Richard B et al. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine 2008;75:408-15.
21. Pentek M, Kobelt G, Szekanecz Z et al. Costs of rheumatoid arthritis in Hungary. J Rheumatol 2007;34: 1437.
22. Verstappen SMM, Jacobs JWG, Kruize AA et al. Trends in economic consequences of rheumatoid arthritis over two subsequent years. Rheumatology 2007;46:968-74.
23. Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology 2006; 45:325-31.
24. Younes M, Jalled A, Aydi Z et al. Socioeconomic impact of ankylosing spondylitis in Tunisia. Joint Bone Spine 2010; 77:41-6.
25. Ara RM, Packham JC, Haywood KL. The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit. Rheumatology 2008;47:68-71.
26. Zhu TY, Tam L, Leung Y et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol 2010; 37:1214-20.
27. Zink A, Askling J, Dixon WG et al. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009;68:1240-6.
28. Tørisen HM. Physician's desk book (In Norwegian: Felleskatalogen). Oslo: Felleskatalogen AS, 2004.
29. Activity based financing. DRG price list (In Norwegian: Innsatsstyrt finansiering 2010). Oslo: Directorate of Health, 2010.
30. Fee schedule for physicians 2010-2011 (In Norwegian: Normaltariff for privat spesialistpraksis). Oslo: Norwegian Medical Association, 2010.
31. Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27(4 Suppl 55):S118-23.
32. Boonen A, Mau W. The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(4 Suppl 55): S112-7.
33. Huscher D, Merkesdal S, Thiele K et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83.
34. Bland JM, Altman DG. Statistics notes: some examples of regression towards the mean. BMJ 1994;309: 780.
35. Sterne JA, White IR, Carlin JB et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.
36. Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis 2009; 68:930-7.
37. Neovius M, Simard JF, Askling J, ARTIS Study Group. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Ann Rheum Dis 2011; 70:1010-15.
38. van den Hout WB. The value of productivity: humancapital versus friction-cost method. Ann Rheum Dis 2010; 69(Suppl 1):i89-91.
39. Zhang W, Anis A. The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol 2011; 1-8.